Literature DB >> 30409798

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Anna B Halpern1,2, Megan Othus3, Emily M Huebner1, Bart L Scott1,4, Paul C Hendrie2,5, Mary-Elizabeth M Percival1,2, Pamela S Becker1,2, Heather A Smith5, Vivian G Oehler1,2, Johnnie J Orozco1,2, Ryan D Cassaday1,2, Kelda M Gardner2, Tara L Chen6, Sarah A Buckley7, Kaysey F Orlowski1, Asma Anwar7, Elihu H Estey1,2, Roland B Walter8,2,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30409798      PMCID： PMC6442971          DOI： 10.3324/haematol.2018.204792

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.

Authors:  Tara L Chen; Elihu H Estey; Megan Othus; Kelda M Gardner; Lauren J Markle; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2013-03-27

2.  Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.

Authors:  Pamela S Becker; Hagop M Kantarjian; Frederick R Appelbaum; Barry Storer; Sherry Pierce; Jianqin Shan; Stephan Faderl; Elihu H Estey
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

3.  Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.

Authors:  Colin D Godwin; Megan Othus; Morgan A Powell; Sarah A Buckley; Elihu H Estey; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2016-01-11

Review 4.  How I treat refractory and early relapsed acute myeloid leukemia.

Authors:  Felicitas Thol; Richard F Schlenk; Michael Heuser; Arnold Ganser
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

5.  Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.

Authors:  Pamela S Becker; Hagop M Kantarjian; Frederick R Appelbaum; Stephen H Petersdorf; Barry Storer; Sherry Pierce; Jianqin Shan; Paul C Hendrie; John M Pagel; Andrei R Shustov; Derek L Stirewalt; Stephan Faderl; Elizabeth Harrington; Elihu H Estey
Journal:  Br J Haematol       Date:  2011-08-18       Impact factor: 6.998

6.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

Authors:  Agnieszka Wierzbowska; Tadeusz Robak; Agnieszka Pluta; Ewa Wawrzyniak; Barbara Cebula; Jerzy Hołowiecki; Sławomira Kyrcz-Krzemień; Sebastian Grosicki; Sebastian Giebel; Aleksander B Skotnicki; Beata Piatkowska-Jakubas; Kazimierz Kuliczkowski; Marek Kiełbiński; Krystyna Zawilska; Janusz Kłoczko; Agata Wrzesień-Kuś
Journal:  Eur J Haematol       Date:  2007-12-11       Impact factor: 2.997

9.  Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Authors:  A B Halpern; M Othus; E M Huebner; S A Buckley; E L Pogosova-Agadjanyan; K F Orlowski; B L Scott; P S Becker; P C Hendrie; T L Chen; M-E M Percival; E H Estey; D L Stirewalt; R B Walter
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

10.  Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Authors:  Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Pamela S Becker; Mary-Elizabeth M Percival; Paul C Hendrie; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Frederick R Appelbaum; Harry P Erba; Elihu H Estey; Roland B Walter
Journal:  Leukemia       Date:  2018-04-17       Impact factor: 11.528
View more
  6 in total

1.  Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

Authors:  Raffaele Palmieri; Sarah A Buckley; Megan Othus; Anna B Halpern; Mary-Elizabeth M Percival; Bart L Scott; Paul C Hendrie; Pamela S Becker; Vivian G Oehler; Elihu H Estey; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2020-02-20

2.  Where do we stand with radioimmunotherapy for acute myeloid leukemia?

Authors:  Roland B Walter
Journal:  Expert Opin Biol Ther       Date:  2022-03-31       Impact factor: 5.589

3.  Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.

Authors:  Ok-Kyong Chaekal; Andromachi Scaradavou; Emeline Masson Frenet; Maria S Albano; Melissa Cushing; Pinkal Desai; Ludy Dobrila; Usama Gergis; Danielle Guarneri; Jing-Mei Hsu; Sangmin Lee; Sebastian A Mayer; Adrienne A Phillips; Nina Orfali; Ellen K Ritchie; Gail J Roboz; Cynthia Romeo; Michael S Samuel; Tsiporah Shore; Koen van Besien
Journal:  Blood Adv       Date:  2020-10-27

4.  How I treat relapsed or refractory AML.

Authors:  Susan DeWolf; Martin S Tallman
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113

5.  Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  Lucas C Zarling; Megan Othus; Brenda M Sandmaier; Filippo Milano; Gary Schoch; Chris Davis; Marie Bleakley; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb; Roland B Walter
Journal:  Leukemia       Date:  2022-04-19       Impact factor: 12.883

6.  Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS).

Authors:  Heather Klocke; Zhao Ming Dong; Craig O'Brien; Nicholas Burwick; Robert E Richard; Daniel Y Wu; Thomas R Chauncey; Solomon A Graf
Journal:  Case Rep Hematol       Date:  2020-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.